Characterizing the swimming properties of artificial bacterial flagella L Zhang, JJ Abbott, L Dong, KE Peyer, BE Kratochvil, H Zhang, ... Nano letters 9 (10), 3663-3667, 2009 | 542 | 2009 |
Incidence and prevalence of nontuberculous mycobacterial lung disease in a large US managed care health plan, 2008–2015 KL Winthrop, TK Marras, J Adjemian, H Zhang, P Wang, Q Zhang Annals of the American Thoracic Society 17 (2), 178-185, 2020 | 196 | 2020 |
Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population TK Marras, C Vinnard, Q Zhang, K Hamilton, J Adjemian, G Eagle, ... Respiratory medicine 145, 80-88, 2018 | 45 | 2018 |
Real-world persistence with dupilumab among adults with atopic dermatitis JI Silverberg, E Guttman-Yassky, A Gadkari, A Kuznik, UG Mallya, ... Annals of Allergy, Asthma & Immunology 126 (1), 40-45, 2021 | 41 | 2021 |
Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US JJ Jalbert, U Chaudhari, H Zhang, J Weyne, JM Shammo Blood 134, 3407, 2019 | 36 | 2019 |
Health care utilization and expenditures following diagnosis of nontuberculous mycobacterial lung disease in the United States TK Marras, M Mirsaeidi, E Chou, G Eagle, R Zhang, M Leuchars, Q Zhang Journal of managed care & specialty pharmacy 24 (10), 964-974, 2018 | 19 | 2018 |
No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab A Blauvelt, A Wollenberg, LF Eichenfield, H Zhang, D Sierka, FA Khokhar, ... Advances in therapy 40 (1), 367-380, 2023 | 12 | 2023 |
Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease TK Marras, M Mirsaeidi, C Vinnard, ED Chan, G Eagle, R Zhang, P Wang, ... Journal of medical economics 22 (11), 1126-1133, 2019 | 10 | 2019 |
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps PW Hellings, AT Peters, AM Chaker, E Heffler, H Zhang, A Praestgaard, ... International Forum of Allergy & Rhinology 12 (7), 958-962, 2022 | 9 | 2022 |
Efficacy and safety of dupilumab maintained in adults≥ 60 years of age with moderate-to-severe atopic dermatitis: analysis of pooled data from four randomized clinical trials JI Silverberg, CW Lynde, K Abuabara, C Patruno, A de Benedetto, ... American journal of clinical dermatology 24 (3), 469-483, 2023 | 8 | 2023 |
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 … C Bachert, J Corren, SE Lee, H Zhang, S Harel, D Cunoosamy, AH Khan, ... International Forum of Allergy & Rhinology 12 (9), 1191-1195, 2022 | 8 | 2022 |
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis AS Paller, JKL Tan, J Bagel, AB Rossi, B Shumel, H Zhang, A Abramova British Journal of Dermatology 186 (3), 496-507, 2022 | 8 | 2022 |
Dupilumab maintains long-term disease control in adults with moderate-to-severe atopic dermatitis as measured by well-controlled weeks: results from the LIBERTY AD CHRONOS … JJ Wu, L Spelman, JL Tan, T Etoh, H Zhang, B Shumel, AB Rossi Dermatology and Therapy 11, 327-330, 2021 | 6 | 2021 |
Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP WW Busse, A Wellman, Z Diamant, NA Cohen, AM Chaker, C Bachert, ... The Journal of Allergy and Clinical Immunology: In Practice 10 (9), 2479 …, 2022 | 5 | 2022 |
Dupilumab provides rapid and sustained improvement in SCORing atopic dermatitis outcomes in paediatric patients with atopic dermatitis A Wollenberg, D Marcoux, JI Silverberg, A Valeria, E Baselga, H Zhang, ... Acta dermato-venereologica 102, 2022 | 5 | 2022 |
Dupilumab treatment provides sustained improvements over 2 years in symptoms and quality of life in adults with atopic dermatitis G Yosipovitch, M de Bruin-Weller, A Armstrong, JJ Wu, P Herranz, D Thaçi, ... Dermatology and therapy 11, 2147-2157, 2021 | 5 | 2021 |
Baseline demographics and severity and burden of atopic dermatitis in adult patients initiating dupilumab treatment in a real-world registry (PROSE) J Bagel, TQ Nguyen, H Lima, N Jain, DM Pariser, S Hsu, G Yosipovitch, ... Dermatology and therapy 12 (6), 1417-1430, 2022 | 4 | 2022 |
Population-based incidence and prevalence of nontuberculous mycobacterial lung disease in a large US managed care health plan, 2008-2015 KL Winthrop, G Eagle, X Li, R Zhang, Q Zhang C25. NON-TUBERCULOUS MYCOBACTERIA: FROM BENCH TO CLINIC, A7651-A7651, 2017 | 4 | 2017 |
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis is efficacious regardless of age of disease onset: a post hoc analysis of two phase 3 clinical trials JI Silverberg, M Boguniewicz, J Hanifin, KA Papp, H Zhang, AB Rossi, ... Dermatology and therapy 12 (12), 2731-2746, 2022 | 3 | 2022 |
AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps S Siddiqui, C Bachert, AM Chaker, JK Han, PW Hellings, AT Peters, ... ERJ Open Research 8 (4), 2022 | 3 | 2022 |